Pulmatrix (NASDAQ: PULM) is developing innovative inhaled therapies to address serious pulmonary diseases, including COPD, fungal infections for Cystic Fibrosis patients, and idiopathic pulmonary fibrosis.
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.